TNF inhibition for ophthalmic indications: current status and outlook

MLA

Andrea D. Birnbaum, et al. “TNF Inhibition for Ophthalmic Indications: Current Status and Outlook.” BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy, vol. 27, no. 4, Apr. 2013. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....e3020e6b455416a3999b47fe26312bfe&authtype=sso&custid=ns315887.

APA

Andrea D. Birnbaum, Lana M. Rifkin, & Debra A. Goldstein. (2013). TNF inhibition for ophthalmic indications: current status and outlook. BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy, 27(4).

Chicago

Andrea D. Birnbaum, Lana M. Rifkin, and Debra A. Goldstein. 2013. “TNF Inhibition for Ophthalmic Indications: Current Status and Outlook.” BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy 27 (4). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....e3020e6b455416a3999b47fe26312bfe&authtype=sso&custid=ns315887.